PowderMed's Vaccines: Out of Chiron, Into the Clinic

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil.

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil. PowderJect's acquisitive history--it got Fluvirin from Celltech Medeva PLC in 2000 [See Deal]—had made it into the world's largest independent vaccines company, complete with a solid US distribution network that complemented Chiron's European presence [See Deal]. The combination of the firms' assets was designed to allow Chiron to compete among the Big Pharma at the top of the vaccines ladder. (See "Chiron/PowderJect: US Snaps Up Europe's Best," In Vivo Europe Rx, July 2003. Also see "Chiron/PowderJect: US Snaps Up Europe's Best" - In Vivo, 1 July, 2003..) So far the move has paid off for Chiron. In 2003, the firm sold $332 million worth of flu vaccines, of which $219 million came from Fluvirin sales, nearly double the £67 million in PowderJect's fiscal year 2002.

Lost in the transatlantic shuffle were a handful of modestly profitable travelers' vaccines and PowderJect's original raison d'être: the powder-injection...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.